This monthly report outlines key developments in China’s antitrust sector for August. The following events merit special attention: SAMR Suspends Antitrust Investigation into DuPont China: In April 2025, SAMR publicly...more
8/15/2025
/ Abuse of Dominance ,
Antitrust Investigations ,
Antitrust Violations ,
Artificial Intelligence ,
China ,
Competition Authorities ,
Enforcement Actions ,
Gun-Jumping ,
Merger Controls ,
Merger Reviews ,
Penalties ,
Popular ,
Price-Fixing ,
State Administration for Market Regulation (SAMR)
In the past half year of 2025, China’s antitrust watchdog has imposed fines on 11 individuals for antitrust violations, including sole proprietors, senior executives, and employees involved in cartels or obstruction of...more
7/11/2025
/ Anti-Monopoly ,
Antitrust Violations ,
Cartels ,
China ,
Civil Liability ,
Compliance ,
Corporate Governance ,
Criminal Prosecution ,
Criminal Sanctions ,
Employees ,
Fines ,
Penalties ,
Personal Liability ,
Risk Management
This monthly report outlines key developments in China’s antitrust sector for June. The following events merit special attention: SAMR Seeks Comments on Provisions for Curbing Acts of Abusing Administrative Power to Eliminate...more
6/20/2025
/ Administrative Authority ,
Anti-Monopoly ,
Antitrust Provisions ,
Application Programming Interface (APIs) ,
Bid Rigging ,
China ,
Collusion ,
Competition ,
Competition Authorities ,
Enforcement ,
Enforcement Actions ,
Government Agencies ,
Monopolization ,
NDRC ,
New Legislation ,
Penalties ,
Personal Liability ,
Pharmaceutical Industry ,
Price-Fixing ,
Proposed Legislation ,
Proposed Rules ,
State Administration for Market Regulation (SAMR) ,
Supply Chain ,
Supply Shortages ,
Supreme Peoples Court ,
Unfair Competition ,
Water Supplies
On May 9, 2025, the Tianjin Municipal Administration for Market Regulation (“Tianjin AMR”) announced administrative penalties against four manufacturers of dexamethasone sodium phosphate (“DSP”) active pharmaceutical...more
5/27/2025
/ Anti-Monopoly ,
Antitrust Provisions ,
Antitrust Violations ,
Cartels ,
China ,
Competition ,
Coronavirus/COVID-19 ,
Corporate Governance ,
Enforcement Actions ,
Healthcare ,
Life Sciences ,
Monopolization ,
Penalties ,
Pharmaceutical Industry ,
Popular ,
Price-Fixing ,
Regulatory Oversight ,
Sanctions
This monthly report outlines key developments in China’s antitrust sector for April. The following events merit special attention...more
4/17/2025
/ Abuse of Dominance ,
Acquisition Agreements ,
Antitrust Provisions ,
China ,
Competition ,
Corporate Sales Transactions ,
Enforcement Actions ,
Government Agencies ,
Hong Kong ,
Merger Agreements ,
Merger Controls ,
Monopolization ,
New Guidance ,
Penalties ,
Pharmaceutical Industry ,
State Administration for Market Regulation (SAMR)